Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Comment: Agminated own goals
Neil H Cox
Readers of this column may not recognise that each of my offerings involves many hours of wading through trivia (and some serious stuff) to find material that may provide some light relief from the daily drudgery. All potential grist to my mill has to be carefully stored and collated (anybody who has seen the opencast filing in my office will know that I’m not being entirely truthful about the careful storage aspect), and something vaguely dermatological inserted, so that I can generate some sort of theme to unleash upon the lucky reader who reputedly reads this page.
Dermatology in practice
2007;
15
(2): 3–3
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
Gilead and LEO announce $1.7bn inflammation deal
Regeneron’s Libtayo shows promise in phase 3 high-risk skin cancer trial
Bristol Myers Squibb shares promising phase 3 results for Sotyktu in psoriatic arthritis
FDA grants approval to Organon’s Vtama cream in atopic dermatitis
EMA committee recommends Galderma’s nemolizumab for prurigo nodularis and atopic dermatitis
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy